Furthermore, we developed a new class of bioengineered antibody-lectin fusion proteins, termed "concabodies," and evaluated their efficacy through <i>in vitro</i> assays and <i>ex vivo</i> experiments using peripheral blood mononuclear cells (PBMCs) from patients with chronic lymphocytic leukemia (CLL).<h4>Results</h4>Myelin protein zero-like 1 (MPZL1) was identified as a novel regulator of OBI-induced DCD, modulating LMP as a key characteristic. Here, MPZL1 is linked to B-cell chronic lymphocytic leukemia.